Rollout Of Covid Vaccine

Karan Kohli

PGP/23/210

Pranav Patki

PGP/23/341

Dhaval Patel

PGP/23/263

Team HBK

IIM Kozhikode

Taher

Lokhandwala

PGP/23/240

Impact Index

Quantification of target markets for entry

World Map

Based on Impact Index developed, Top 10 priority countries for Cure& were identified

9.09%

Population > 65

years old

Data source: WHO, European Center for Disease Prevention and Control (ECDC), World Bank

26m+cases

870k+deaths

Global impact

Data as on 5th September 2020

Most vulnerable age

group

(2019 estimate)

Spread of the virus

Countries more impacted by the pandemic

would have a greater need of the vaccine

#cases, # new cases, # deaths, # cases per mn

Vulnerable population

Countries with a larger vulnerable population

would have a greater need for a vaccine

Median age, % population over 65, %

smokers, diabetes prevalence

Strictness of response

The strictness of countries’ responses will

govern the need for a vaccine

Stringency index

Healthcare levels

Countries focusing more on healthcare will

want quicker access to protect their population

$ spend Government per capita, $ spend per

capita population, beds per thousand

Impact Index

Low High

1.USA

2.India

3.Brazil

4.France

5.China

6.Germany

7.Sweden

8.Luxembourg

9.Belgium

10.Spain

Cure& should focus on –

in the beginning, before expanding to

other possible geographies

*Refer to Slide #17 for Impact Index analysis Excel

India and USA are the best market to enter based on qualitative parameters and impact

index

India Brazil France China

•India hosts SII –the

largest global vaccine

manufacturer

•Part of the COVAX

Alliance

•Favorable to

manufacturing

•Increased regulatory

compliance

•Phase 3 trials- Oxford &

AstraZeneca, Sinovac

Biotech, Pfizer &

BioNTech, J&J

•Talks with Oxford &

AstraZeneca for 100mn

vaccine doses

•Part of the COVAX

alliance

•Healthcare national

responsibility

•Mandatory social health

insurance

•Signed deal to Pre-order

400mn Vaccines

•SinoVac has been said to

be ready for use for the

Chinese military

•More than half of 17

candidate vaccines

identified by WHO that

are in clinical evaluation

involve Chinese

companies or institutes.

•President has

announced the possible

vaccines will not be

mandatory for all

•Poor IP protection

history

•Sanofi €610mn

investment in vaccine

plant & R&D

•Sanofi and French

Government aligned on

several other projects

•Unreliable COVID 19

data make delivery

challenging

•Poor IP protection

history

•Operations Warp Speed

–for accelerated

•Pfizer and Biontech in

agreement with 600 Mn

Doses of mRNA based

candidate (July 2020)

•Not a part of the COVAX

Alliance

USA

•Uncertainty of market

due to leadership and

political dissonance

Suppliers for APIs and other key components are identified and evaluated using

technical, manufacturing, regulatory and business sense parameters

Active

Ingredient

Cell Culture materials

Purification materials

Inactivating agents

Preservatives

Adjuvants

Key Areas of sourcing requirements

MANUFACTURING &

CONTAINMENT QUALITY & REGULATORY

Parameters for Evaluation of API Suppliers

TECHNICAL CAPABILITIES

•Facilities: Age, equipment, failure

history, cleanliness etc.

•Production Process: Material

flow, airflow, contamination

potential, review deviations, etc.

•Scalability & Personnel

•Specific regulatory requirements

•Audit History

•Quality Assurance capabilities